Experts urge shorter, evidence-based antibiotic courses over traditional “finish the course” rule

Infectious-disease specialists are re-evaluating the entrenched instruction to take every antibiotic pill, arguing that the rationale—preventing relapse and resistance—has been overstated. Early penicillin use revealed variable cure times, and later guidance from the CDC and WHO linked unfinished courses to resistant bugs, a link that research now disputes. Studies of urinary-tract infections, pneumonia and bloodstream infections demonstrate that three- to seven-day courses often match longer treatments in efficacy while reducing disruption to the gut microbiome and limiting selection pressure for resistant strains.

Nonetheless, severe or deep-seated infections may still demand extended therapy, and clinicians must consider pathogen, tissue penetration and host immunity. A 2025 review found roughly a third of antibiotic prescriptions worldwide are unnecessary, especially for viral colds and sinus issues. Physicians are urged to prescribe only when needed, rely on up-to-date trial data for duration, and counsel patients on expected recovery timelines.